Group 1: Industry Overview - The petroleum and chemical indices mostly rose last week, with the chemical raw materials index down by 0.98%, the chemical machinery index up by 0.83%, the chemical pharmaceuticals index up by 2.47%, and the pesticide and fertilizer index up by 0.71% [1] - In the petroleum sector, the petroleum processing index rose by 0.81%, the petroleum extraction index rose by 1.41%, while the petroleum trade index fell by 7.98% [1] - International crude oil prices experienced narrow fluctuations, with WTI settling at $60.79 per barrel, down 1.20% from May 23, and Brent settling at $63.90 per barrel, down 1.36% [1] Group 2: Market Performance - The top five performing listed chemical companies in the Shanghai and Shenzhen markets last week were Lianhua Technology up by 38.97%, Baismei up by 25.00%, Suqian Liansheng up by 16.80%, Qingdao Jinwang up by 18.23%, and Honghe Technology up by 17.09% [2] - The bottom five performing listed chemical companies were Guangju Energy down by 15.95%, Tianan New Materials down by 14.66%, Hongbaoli down by 13.10%, Annada down by 12.38%, and Heimao Co. down by 12.14% [2] Group 3: Product Price Changes - The top five rising petrochemical products included hydrochloric acid up by 35.42%, liquid chlorine up by 21.85%, glyphosate up by 6.15%, dichloromethane up by 4.36%, and paraquat up by 4.35% [1] - The top five declining petrochemical products included acrylic acid down by 9.74%, butadiene down by 9.60%, natural rubber down by 6.55%, styrene-butadiene rubber down by 6.13%, and aniline down by 5.95% [1]

Group 1 - The market is expected to continue its upward trend, with 82 stocks hitting the daily limit up, indicating a bullish sentiment [2] - The current market shows a divergence between large-cap indices and small-cap indices, suggesting that existing funds are actively trading while new capital remains cautious [2][3] - Key sectors identified for potential investment this week include digital currency, pharmaceuticals, and agrochemicals, which are expected to show sustained performance [3] Group 2 - The digital currency sector is closely linked to cross-border payments, indicating strong growth potential [3] - The pharmaceutical sector has significant ties to chemical manufacturing, suggesting ongoing relevance and investment opportunities [3] - The agrochemical sector is experiencing a resurgence, highlighting its importance in the current market landscape [3]

Investment Rating - The report assigns an "Overweight" rating to the pharmaceutical and biotechnology industry, indicating that the industry index is expected to outperform the CSI 300 index by 10% or more over the next six months [2][37]. Core Insights - The pharmaceutical and biotechnology sector saw an overall increase of 2.21% in the week from May 26 to May 30, ranking second among 31 industries in the Shenwan index and outperforming the CSI 300 index by 3.29 percentage points. Year-to-date, the sector has risen by 6.61%, ranking sixth among the 31 industries and outperforming the CSI 300 index by 9.02 percentage points [4][13][15]. - The current PE valuation for the pharmaceutical and biotechnology sector is 27.98 times, which is at the historical median level, with a valuation premium of 137% compared to the CSI 300 index. The top three sub-sectors in terms of growth are chemical pharmaceuticals, biological products, and medical services, with increases of 3.83%, 3.14%, and 2.46% respectively [4][22][15]. Summary by Sections Market Performance - The pharmaceutical and biotechnology sector's performance for the week of May 26 to May 30 was a 2.21% increase, ranking second among 31 industries, and outperforming the CSI 300 index by 3.29 percentage points. Year-to-date, the sector has increased by 6.61%, ranking sixth and outperforming the CSI 300 by 9.02 percentage points. The top three sub-sectors were chemical pharmaceuticals (3.83%), biological products (3.14%), and medical services (2.46%) [4][13][15]. Industry News - On May 29, the National Medical Products Administration (NMPA) approved 11 innovative drugs, with 9 being domestically developed, showcasing the increasing innovation capability of China's pharmaceutical industry. Additionally, during the 2025 American Society of Clinical Oncology (ASCO) annual meeting, significant clinical data was presented for various treatments, indicating the growing recognition of domestic innovative drug companies [5][29][32]. Investment Recommendations - The report suggests focusing on the innovative drug sector, which is seen as the most certain and leading sub-sector within the pharmaceutical and biotechnology industry. It also recommends exploring investment opportunities in medical devices, traditional Chinese medicine, chain pharmacies, and medical services. Specific stock recommendations include Beida Pharmaceutical, Teva Biopharma, Qianhong Pharmaceutical, Lingrui Pharmaceutical, and Lao Baixing, with additional stocks to watch including Kelun Pharmaceutical, Rongchang Biopharma, Kaili Medical, Huaxia Eye Hospital, and Baipusais [6][35].

2025 年 06 月 03 日 北交所行业研究 研究所： 证券分析师： 罗琨 S0350522110003 luok@ghzq.com.cn 联系人 ： 禹露 S0350124070012 yul06@ghzq.com.cn [Table_Title] 本周北交所流动性收缩，世昌股份/志高机械上 会通过 ——北交所行业周报 | 行业相对表现 | | | 2025/05/30 | | | --- | --- | --- | --- | --- | | 表现 | | 1M | 3M | 12M | | 北证 | 50 | 8.96% | 3.12% | 79.99% | | 沪深 | 300 | 1.73% | -3.22% | 6.27% | 相关报告 《北交所行业周报：本周北证 50 阶段性回调，下 周世昌股份/志高机械上会、交大铁发申购（推荐） *中小盘*罗琨》——2025-05-26 《北交所行业周报：本周北证 50 继续领涨，交投 活跃度持续上升，天工股份正式上市（推荐）*中 小盘*罗琨》——2025-05-19 《北交所行业周报：本周北证 50 实现领涨、交投 活跃度明显提升，下周天工股份上市（推荐 ...

从K线图上来看，沪指3日一举突破了5日、10日、20日三根均线，与上周四大盘一举站上5日均线和10 日均线非常相似，就在大家都在看涨的时候，第二天就收出一根中阴线，将不少追涨的投资者套住。只 是与上周五不同的是，上周五是端午节之前，资金有担心节日利空撤离避险的需要，而3日已经是节 后，没有了这个需要，因此4日立即收出中阴线的概率不大。但是，近几个交易日持续上涨的可能性也 不大。主要有两个原因，一是成交量还维持在1.2万亿元以下，二是主力资金3日净流出95亿多元。也就 是说，目前大盘还处于上涨不放量的状态，因此，上涨持续性缺乏支撑，大盘大概率将继续在3330点到 3400点之间窄幅震荡。 3日湖南板块表现还可以。146只个股有93只上涨。3只涉医药或医美概念的个股华纳药厂、水羊股份、 九芝堂涨超10%。华纳药厂以20%领涨。 华纳药厂的主营业务为化学原料药、化学药制剂和中药制剂的研发、生产与销售。2025年一季报每股收 益0.44元，归母净利润4121.36万元，净利润同比增长-31.37%。 长沙晚报掌上长沙6月3日讯（全媒体记者 刘军）A股三大指数3日集体小幅上扬。截至收盘，沪指涨 0.43%，收报3361 ...

A股收评：沪指收涨0.43% 创新药板块持续冲高 金十数据6月3日讯，A股三大指数集体低开高走，维持反弹走势。截止至今日收盘，沪指收涨0.43%， 深成指收涨0.16%，创业板指收涨0.48%。盘面上，创新药板块午后持续冲高，舒泰神、华纳药厂等多 股涨停。黄金股领涨，西部黄金涨停。稳定币概念全天走强，恒宝股份、御银股份、翠微股份涨停。中 韩自贸区、培育钻石、乳业、游戏板块涨幅居前，钢铁、汽车整车、白酒、煤炭开采加工板块跌幅居 前。全市场超3390只个股飘红，沪深两市成交额超1.14万亿元。 ...

Group 1 - The report highlights the relationship between contract goods and industrial enterprise profits, indicating that inventory destocking and order prosperity are key directions for asset allocation [5][7] - In May 2025, the manufacturing PMI improved to 49.5%, reflecting a slight recovery in manufacturing market demand, although it remains below the first quarter average [11][12] - The report notes that the domestic equity market showed a mixed performance, with 18 industries rising and 13 falling, indicating sector-specific dynamics [6][20] Group 2 - The report discusses the impact of external factors such as the U.S. increasing steel import tariffs to 50%, which may affect related industries [17] - It mentions the extension of certain exemptions from the U.S. Section 301 tariffs on China, which could influence trade dynamics [19] - The report emphasizes the need for policies to support growth in light of ongoing economic challenges, particularly in the real estate sector [11][14] Group 3 - The analysis of industrial enterprise profits shows a 3.0% year-on-year increase in April 2025, despite a 2.7% decline in the Producer Price Index (PPI), suggesting a complex relationship between costs and profitability [7][8] - The report identifies sectors such as agricultural product processing and electrical machinery as performing well, while sectors like automotive and power equipment faced declines [6][8] - The report indicates that the recovery in manufacturing is supported by a decrease in raw material costs, which may benefit midstream manufacturing leaders [7][8]

长江电力 东方财富 02)中国核电 1951.90亿市值 7330.68亿市值 3284.08亿市值 15.40亿成交额 4.28亿成交额 23.58亿成交额 20.78 29.96 9.49 -0.24(-0.79%) -0.09(-0.94%) +0.16(+0.78%) 食品饮料 证券 中信证券 国泰海通 海天味业 ■双 3808.88亿市值 3169.82亿市值 2455.01亿市值 9.24亿成交额 19.31亿成交额 3.88亿成交额 25.70 17.98 44.15 +0.18(+0.71%) +0.80(+4.66%) -0.27(-0.61%) 消费电子 化学制药 恒瑞医药 立讯精密 工业富联 3747.37亿市值 2201.05亿市值 3663.63亿市值 5.37亿成交额 11.33亿成交额 15.91亿成交额 55.48 30.37 18.87 -0.06(-0.32%) -0.03(-0.10%) +0.74(+1.35%) 家电行业 农牧饲渔 牧原股份 格力电器 海尔智家 油气长官 2525.11亿市值 2326.02亿市值 2241.92亿市值 23.68亿成交额 5.79亿成 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [7] Core Views - The company is focusing on chronic diseases, tumors, and immunology, covering four major business segments: pharmaceutical manufacturing, pharmaceutical commerce, medical aesthetics, and industrial microbiology. It is continuously optimizing its product structure and transitioning from generics to innovation. The core products of its subsidiary, China Medical East, are maintaining stable market growth and increasing market share. The medical aesthetics segment is showing growth potential, and the innovative pipeline is entering a harvest period. The projected net profits for 2025-2027 are estimated at 40.61 billion, 47.16 billion, and 55.37 billion yuan, with corresponding EPS of 2.32, 2.69, and 3.16 yuan, leading to PE ratios of 16.3, 14.0, and 11.9 times, respectively [7][8][10]. Summary by Sections Company Overview - The company, established in 1993 and listed in 1999, has developed into a large comprehensive pharmaceutical company covering the entire pharmaceutical industry chain. It has transitioned towards a research and innovation-driven pharmaceutical enterprise since 2018 [18]. Business Performance - The company reported a revenue of 419.1 billion yuan in 2024, a year-on-year increase of 3.2%, and a net profit of 35.1 billion yuan, up 23.7% year-on-year. The pharmaceutical manufacturing segment generated 138.1 billion yuan in revenue, growing by 13.1%, while the medical aesthetics segment saw a slight decline in revenue [8][22]. Innovative Pipeline - The company is focusing on three core areas: oncology, endocrinology, and autoimmune diseases, with a differentiated layout in ADC and PROTAC technologies. The innovative pipeline includes over 80 projects, with several products entering clinical stages. The company is also actively pursuing collaborations and acquisitions to enhance its product offerings [9][39][55]. Financial Summary - The company’s financial metrics show steady growth, with projected revenues of 44.68 billion, 47.95 billion, and 51.83 billion yuan for 2025, 2026, and 2027, respectively. The gross margin is expected to improve from 33.6% in 2025 to 35.4% in 2027, while the net profit margin is projected to increase from 9.1% to 10.7% over the same period [10][28].

投资者： 最近流感又有抬头的趋势，公司目前在流感产品这块有什么竞争力？ 董秘： 尊敬的投资者，您好！公司致力于成为全品种、全剂型的抗流感领军企业，并不断丰富感冒相 关产品线，目前公司在感冒与抗病毒相关领域已逐步覆盖注射、口服、吸入等多种给药途径的剂型，涉 及抗流感病毒感染、抗细菌感染、解热镇痛等多个治疗领域，形成丰富、完整、高效的产品系列。感谢 您的关注！ 当日关注点 交易信息汇总 截至2025年5月30日收盘，南新制药(688189)报收于7.06元，上涨1.0%，换手率3.09%，成交量8.47万 手，成交额6000.36万元。 董秘最新回复 投资者： 看到报道说公司的产品已经在京东上销售了，是真的吗？ 董秘： 尊敬的投资者，您好！公司结合市场形势要求，公司不断拓宽营销网络建设，目前线上已在京 东平台进行销售，线下组建多层次营销渠道，在多个省市派驻专门人员，构建了覆盖全国的营销网络， 从而更好地服务于终端客户。感谢您的关注！ 5月30日，南新制药的资金流向显示主力资金净流入615.34万元；游资资金净流入42.47万元；而散户资 金则净流出657.81万元。 交易信息汇总：5月30日主力资金净流入615. ...